An typical example is TNFAIP3 mutation indicates low responses to PD-1 inhibitor in NSCLC and cervical cancer patients as showed in the present study, which is also supported by a study on melanoma [52]. This evidence concerns the gene TNFAIP3 and non-small cell lung carcinoma.